- CONSORT Statement
- CONSORT Statement Extensions
- Evidence underpinning CONSORT
- Accrual and sample size
- Attitudes to trials
- Adverse events (Harms)
- Baseline data
- Blinding
- Compliance
- Early stopping
- Eligibility
- Follow-up
- Funding
- Generalizability
- Harms
- Intention to treat
- Interpretation
- Interventions
- Outcome reporting
- Random allocation
- Recruitment
- Statistical analysis
- Statistical methods
- Trial design issues
- Trial registration
- Uptake of CONSORT by journals
- Impact of and adherence to CONSORT
- Endorsement of CONSORT
Baseline data
Altman DG, Dore CJ. Randomisation and
baseline comparisons in clinical trials. Lancet 1990; 335(8682):149-153.
PMID: 1967441
Assmann SF, Pocock SJ, Enos LE,
Kasten LE. Subgroup analysis and other (mis)uses of
baseline data in clinical trials. Lancet 2000; 355(9209):1064-1069.
PMID: 10744093
Bailey KR. Clinical trials in acute myocardial infarction:
when should we adjust for baseline characteristics? Am Heart J 2000;
139(5):761-763.
PMID: 10783205
Enas GG, Enas NH, Spradlin CT, Wilson MG, Wiltse CG. Baseline comparability in clinical trials: prevention of poststudy anxiety. Drug Information Journal 1990; 24:541-548.
Hall JC, Hall JL. Baseline comparisons in surgical trials.
ANZ J Surg 2002; 72(8):567-569.
PMID: 12190730
Steyerberg EW, Bossuyt PM, Lee KL. Clinical trials in acute
myocardial infarction: should we adjust for baseline characteristics? Am Heart
J 2000; 139(5):745-751.
PMID: 10783203
Page last edited: 05 May 2009
